Rabies-virus-glycoprotein-pseudotyped recombinant baculovirus vaccine confers complete protection against lethal rabies virus challenge in a mouse model

Vet Microbiol. 2014 Jun 25;171(1-2):93-101. doi: 10.1016/j.vetmic.2014.03.037. Epub 2014 Apr 3.

Abstract

Rabies virus has been an ongoing threat to humans and animals. Here, we developed a new strategy to generate a rabies virus vaccine based on a pseudotyped baculovirus. The recombinant baculovirus (BV-RVG/RVG) was pseudotyped with the rabies virus glycoprotein (RVG) and also simultaneously expressed another RVG under the control of the immediate early CMV promoter. In vitro, this RVG-pseudotyped baculovirus vector induced syncytium formation in insect cells and displayed more efficient gene delivery into mammalian cells. Mice immunized with BV-RVG/RVG developed higher levels of virus-neutralizing antibodies, and conferred 100% protection against rabies viral challenge. These data indicate that the RVG-pseudotyped baculovirus BV-RVG/RVG can be used as an alternative strategy to develop a safe and efficacious vaccine against the rabies virus.

Keywords: Glycoprotein; Pseudotyped baculovirus; Rabies virus; Vaccine.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Viral / immunology*
  • Baculoviridae / genetics*
  • Cell Line
  • Cell Line, Tumor
  • Cricetinae
  • Disease Models, Animal
  • Female
  • Glycoproteins / genetics
  • Glycoproteins / immunology
  • HeLa Cells
  • Humans
  • Mice
  • Mice, Inbred BALB C
  • Rabies / prevention & control*
  • Rabies Vaccines / genetics
  • Rabies Vaccines / immunology*
  • Rabies virus / genetics*
  • Sf9 Cells
  • Vaccines, Synthetic / genetics
  • Vaccines, Synthetic / immunology*
  • Viral Envelope Proteins / genetics
  • Viral Envelope Proteins / immunology*

Substances

  • Antibodies, Viral
  • Glycoproteins
  • Rabies Vaccines
  • Vaccines, Synthetic
  • Viral Envelope Proteins